Is it worth carrying out ultrasound-magnetic resonance imaging fusion targeted biopsy on Prostate Imaging Reporting and Data System score 3 prostate lesions?
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- INTERNATIONAL JOURNAL OF UROLOGY27(5) · pp.431 · 2020
- 피인용
- Web of Science 1Scopus 1
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 2.445
- ISSN
- 0919-8172
저자
- 김경환제1저자Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- 구자윤Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- 박원영Department of Pathology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- 홍승백Department of Radiology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- 김석Department of Radiology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- 하홍구교신저자Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
초록
Objectives To evaluate the use of ultrasound-magnetic resonance imaging fusion targeted biopsy for Prostate Imaging Reporting and Data System 3 prostate lesions. Methods We identified 227 patients with prostate-specific antigen levels >= 4 ng/mL who underwent concurrent transrectal ultrasound-guided systemic biopsy and fusion biopsy. Suspicious prostatic lesions were assessed in accordance with Prostate Imaging Reporting and Data System version 2.0. We compared ultrasound-magnetic resonance imaging fusion targeted biopsy and ultrasound-guided biopsy cancer detection rates in Prostate Imaging Reporting and Data System 3 lesions with those in other Prostate Imaging Reporting and Data System score lesions. In Prostate Imaging Reporting and Data System 3 patients, we identified clinically significant prostate cancer risk factors by logistic regression analysis. Results In total, 2770 transrectal ultrasound-guided and 867 fusion biopsy cores were obtained; where 332 (12.0%) and 194 (22.4%) cores were prostate cancer-positive, respectively (P < 0.001). The fusion biopsy cancer detection rate (8.0%) in Prostate Imaging Reporting and Data System 3 lesions was similar to that in Prostate Imaging Reporting and Data System 1-2 lesions, but was lower than that of Prostate Imaging Reporting and Data System 4 (30.0%; P < 0.001) and 5 lesions (65.2%; P < 0.001), and ultrasound-guided biopsy (12.0%; P = 0.023). For clinically significant prostate cancer detection, fusion biopsy in Prostate Imaging Reporting and Data System 3 lesions was inferior to that in Prostate Imaging Reporting and Data System 4 and 5 lesions, and non-superior to ultrasound-guided biopsy. Cancer detection rate trends were similar in biopsy-naive patients. In Prostate Imaging Reporting and Data System 3 patients, prostate-specific antigen density was the only significant predictor of clinically significant prostate cancer. Conclusions The present findings do not support the use of ultrasound-magnetic resonance imaging fusion targeted biopsy for Prostate Imaging Reporting and Data System 3 lesions. Thus, we recommend the use of transrectal ultrasound-guided systemic biopsy for patients with Prostate Imaging Reporting and Data System 3 index lesions.
키워드
biopsydiagnosismagnetic resonance imagingprostate cancerultrasonographyDIAGNOSTIC-ACCURACYRISK STRATIFICATIONEQUIVOCAL LESIONSCANCER DETECTIONGUIDED BIOPSYVERSION 2MRICATEGORY
식별자
- Scopus EID
- 2-s2.0-85081985956
- WoS UID
- 000520277200001



로그인
연구물 목록으로